Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 8.08Caplin Point Laboratories Ltd. demonstrates exceptional financial health, characterized by outstanding profitability, robust growth, and a nearly debt-free balance sheet. The company is highly effective at turning revenue into profit and is expanding its sales and earnings at an impressive rate. Its ability to cover all its financial obligations is superb, indicating very low financial risk. The primary area for attention is its operational efficiency. The company takes a considerable amount of time to sell its products and collect payments from customers, which ties up cash. Furthermore, it is currently investing very heavily in new assets. While this points to future growth ambitions, it is a significant cash outflow in the present. Overall, Caplin Point is a financially secure and rapidly growing company, with its main challenge lying in optimizing its day-to-day operational cycle.
Health Score : 8.08Caplin Point Laboratories Ltd. demonstrates exceptional financial health, characterized by outstanding profitability, robust growth, and a nearly debt-free balance sheet. The company is highly effective at turning revenue into profit and is expanding its sales and earnings at an impressive rate. Its ability to cover all its financial obligations is superb, indicating very low financial risk. The primary area for attention is its operational efficiency. The company takes a considerable amount of time to sell its products and collect payments from customers, which ties up cash. Furthermore, it is currently investing very heavily in new assets. While this points to future growth ambitions, it is a significant cash outflow in the present. Overall, Caplin Point is a financially secure and rapidly growing company, with its main challenge lying in optimizing its day-to-day operational cycle.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
21.83
Industry Median
36.13
Small Cap Median
35.79
P/E RATIO
23.97
P/B RATIO
4.07
Industry Median
6.08
Small Cap Median
6.08
P/S RATIO
N/A
Industry Median
5.75
Small Cap Median
5.17
Others
PEG RATIO
1.17
EV/EBITDA RATIO
17.28
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1691.3 as on May 29, 2026.
Growth Score : 10.00The company is on an exceptional growth trajectory. It is successfully expanding its business across all key financial metrics, including revenue, operating profit, and net income. This comprehensive and robust growth demonstrates strong market demand, effective strategic execution, and a solid competitive position. The expansion of its asset base further indicates a commitment to future growth, painting a very positive picture for its long-term prospects.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 19.6 | 15.6 | 15.47 | 14.34 | 12.91 |
| Operating Profit Growth Rate | 20.06 | 11.9 | 24.89 | 17.93 | 16.9 |
| Earnings Per Share (EPS) Growth | 23.51 | 25.3 | 21.42 | 17.23 | 19.56 |
| Asset Growth Rate | 27.27 | 26.21 | 23.14 | 18.9 | 26.09 |
| Net Income Growth Rate | 22.71 | 22.4 | 22.28 | 17.35 | 20.15 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Caplin Point Laboratories Ltd | 8.08 | 23.97 | Neutral | 761.00 | 52.17 | 650.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Caplin Point Laboratories Ltd. is a pharmaceutical company primarily focused on manufacturing and marketing a wide range of injectable and ophthalmic products. It specializes in catering to emerging markets, particularly in Latin America, Africa, and French-speaking regions, with a strong emphasis on quality and affordability, alongside a growing presence in regulated markets.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Caplin Point Laboratories Ltd's P/E ratio (TTM) is 21.83, compared to the industry median of 36.13 and large cap median of 35.79.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Caplin Point Laboratories Ltd's P/B ratio is 4.07, compared to the industry median of 6.08 and large cap median of 6.08.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Caplin Point Laboratories Ltd's P/S ratio is N/A, compared to the industry median of 5.75 and large cap median of 5.17.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Caplin Point Laboratories Ltd's PEG ratio is 1.17.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Caplin Point Laboratories Ltd's EV/EBITDA ratio is 17.28.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Caplin Point Laboratories Ltd's ROE is 18.13%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Caplin Point Laboratories Ltd's ROA is 18.81%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Caplin Point Laboratories Ltd's ROCE is 25%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Caplin Point Laboratories Ltd's operating margin is 34.80%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Caplin Point Laboratories Ltd's net margin is 29.72%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Caplin Point Laboratories Ltd's current ratio is 5.22.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Caplin Point Laboratories Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Caplin Point Laboratories Ltd's interest coverage ratio is 804.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Caplin Point Laboratories Ltd's DPS is ₹4.22.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Caplin Point Laboratories Ltd's EPS is 19.56.
(Source line: "Ratios as of 11 Oct 2026, based on last traded price of ₹1691.30. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1990
Headquarters: Chennai, Tamil Nadu
Core Offerings: Injectable products, Ophthalmic products, Creams, Liquids, Gels
Stock Listing: NSE (CAPLIPOINT), BSE (524742)
Promoter: Mr. C.C. Paarthipan / Promoter Group
1990: Incorporated in Chennai, India.
1994: Commenced commercial operations.
Early 2000s: Began focusing on emerging markets in Latin America and Africa.
2010s: Expanded manufacturing capabilities and diversified product portfolio, including specialized injectables.
2015: Listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
Present: Established a strong presence in numerous emerging markets and made inroads into regulated markets like the USA.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Latin America | ~58% | Operating Profit |
| Africa | ~24% | Operating Profit |
| Regulated Markets (USA & EU) | ~15% | Operating Profit |
| India & Rest of World | ~3% | Operating Profit |
Emerging Markets Focus: Dominant revenue contribution from Latin America and Africa, offering essential and specialized pharmaceutical products tailored to these regions.
Regulated Markets Expansion: Growing presence in the US and European markets, primarily focusing on niche injectable products manufactured from USFDA-approved facilities.
Product Diversification: Strong emphasis on high-value products such as injectables (small volume parenterals, pre-filled syringes), ophthalmic preparations, and a range of sterile and non-sterile formulations.
Mr. C.C. Paarthipan (Chairman & Managing Director): Founder of Caplin Point, he has been the visionary force behind the company's strategic focus on emerging markets and its growth trajectory. He holds over three decades of experience in the pharmaceutical industry.
Caplin Point Laboratories (USA) Inc. (USA subsidiary)
Caplin Point Singapore Pte. Ltd. (Singapore subsidiary)
Caplin Steriles Limited (Indian subsidiary focused on sterile injectables)
Bonus Issue (1:2 ratio) in 2023. Stock Split (1:10) in 2021. Bonus Issue (1:1 ratio) in 2017.
The Caplin Point Laboratories Ltd share price today is ₹1691.30 on NSE (CAPLIPOINT), as of 11 Oct 2026.
As of 11 Oct 2026, Caplin Point Laboratories Ltd share price is ₹1691.30, with previous close ₹1691.30. Today's range is ₹1691.30 to ₹1691.30. The 52-week range is ₹N/A to ₹N/A.
As of today, Caplin Point Laboratories Ltd's market cap is ₹12,853.88 crore (Mid Cap).
Caplin Point Laboratories Ltd's current P/E ratio is 21.83, compared to the Pharmaceuticals & Biotechnology sector average of N/A.
Caplin Point Laboratories Ltd's current P/B ratio is 4.07.
Caplin Point Laboratories Ltd's current dividend yield is 0.25%. Last dividend of ₹2.50 per share was declared on 08-Aug-2023.
Caplin Point Laboratories Ltd's EPS (TTM) is ₹19.56.
Caplin Point Laboratories Ltd. is a pharmaceutical company primarily focused on manufacturing and marketing a wide range of injectable and ophthalmic products. It specializes in catering to emerging markets, particularly in Latin America, Africa, and French-speaking regions, with a strong emphasis on quality and affordability, alongside a growing presence in regulated markets.
Caplin Point Laboratories Ltd is promoted by Mr. C.C. Paarthipan / Promoter Group, holding 70.57% as of 11 Oct 2026.
Caplin Point Laboratories Ltd is listed on NSE (CAPLIPOINT) and BSE (524742). Its next quarterly results are expected on August 2024.
Operating Cash Flow Ratio